Tempus AI TEM is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, ...

Tempus AI (TEM) just secured FDA 510(k) clearance for its new AI driven diagnostic tools, a milestone that could shift how investors think about the company’s role in precision oncology. See our ...

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies. The company grew its ...

Investing.com - TD Cowen has reiterated its Hold rating on Tempus AI Inc (NASDAQ:TEM) with a price target of $88.00, aligning with the broader analyst consensus of 2.14 (where 1 is Strong Buy and 5 is ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Key attitudes and strategic frameworks for intelligent and successful investors Marguerita is a Certified Financial Planner (CFP), Chartered Retirement Planning Counselor (CRPC), Retirement Income ...